At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 535 enrolled
Drug / intervention
Omega-3 supplements +1 moredrug
Likely dose
Omega-3 supplements 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dry Eye Assessment and Management Study
In Brief
A Phase 3 clinical trial evaluating Omega-3 supplements and Placebo for Dry Eye. Completed, enrolled 535 participants across 27 sites.
Detailed Summary
The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
CollaboratorsNational Eye Institute (NEI)
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartNov 2014
Primary CompletionSep 2017
Study CompletionJan 2020
TodayJul 2026
First PostedMay 1, 2014
Enrollment StartNov 1, 2014
Primary CompletionSep 5, 2017
Study CompletionJan 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.2 years ago
Interventions
Omega-3 supplementsdrug
2000 mg EPA and 1000 mg DHA per day
Placebodrug
Olive oil gelcaps manufactured to mimic Omega-3 gelcaps